{"id":"linezolid-l","safety":{"commonSideEffects":[{"rate":"2-3","effect":"Thrombocytopenia"},{"rate":"1-2","effect":"Anemia"},{"rate":"3-11","effect":"Nausea"},{"rate":"2-11","effect":"Diarrhea"},{"rate":"0.5-2","effect":"Headache"},{"rate":"0.3-2","effect":"Peripheral neuropathy"},{"rate":"0.3-1","effect":"Optic neuropathy"}]},"_chembl":null,"_dailymed":{"setId":"6e70e63b-bfd5-478d-a8ee-8ba22c9efabd","title":"ZYVOX (LINEZOLID) INJECTION, SOLUTION ZYVOX (LINEZOLID) GRANULE, FOR SUSPENSION ZYVOX (LINEZOLID) TABLET, FILM COATED [PHARMACIA & UPJOHN COMPANY LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Linezolid is an oxazolidinone antibiotic that binds to the bacterial 50S ribosomal subunit and blocks the initiation of protein synthesis. This mechanism is bacteriostatic, halting bacterial growth and allowing the immune system to clear the infection. It is effective against both gram-positive and gram-negative bacteria, including resistant strains such as MRSA and VRE.","oneSentence":"Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:19:05.328Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Vancomycin-resistant Enterococcus faecium (VRE) infections"},{"name":"Methicillin-resistant Staphylococcus aureus (MRSA) infections"},{"name":"Nosocomial pneumonia"},{"name":"Complicated skin and soft tissue infections"},{"name":"Community-acquired pneumonia"}]},"trialDetails":[{"nctId":"NCT07477119","phase":"PHASE4","title":"Linezolid Tolerance During the BPaL Regimen With Dosage Personalization Based on Therapeutic Drug Monitoring (TDM) During Multidrug-Resistant Tuberculosis Treatment","status":"NOT_YET_RECRUITING","sponsor":"Marco Schiuma","startDate":"2026-03","conditions":"Linezolid, Tuberculosis Multi Drug Resistant Active, Therapeutic Drug Monitoring (TDM)","enrollment":150},{"nctId":"NCT07170800","phase":"PHASE2","title":"A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets","status":"RECRUITING","sponsor":"WestVac Biopharma Co., Ltd.","startDate":"2025-09-19","conditions":"Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis","enrollment":60},{"nctId":"NCT06590428","phase":"NA","title":"Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis","status":"RECRUITING","sponsor":"Albert Einstein College of Medicine","startDate":"2026-03","conditions":"Rifampin-resistant Tuberculosis, Drug-resistant Tuberculosis","enrollment":280},{"nctId":"NCT06905522","phase":"PHASE3","title":"A PAN-USR TB Multi-Center Trial","status":"RECRUITING","sponsor":"Shenzhen Third People's Hospital","startDate":"2025-06-18","conditions":"Pulmonary Tuberculosis","enrollment":610},{"nctId":"NCT06114628","phase":"PHASE2","title":"Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB","status":"RECRUITING","sponsor":"University College, London","startDate":"2024-01-09","conditions":"Pulmonary Tuberculosis","enrollment":2500},{"nctId":"NCT07198685","phase":"NA","title":"6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province","status":"NOT_YET_RECRUITING","sponsor":"Wuhan Pulmonary Hospital","startDate":"2025-09-30","conditions":"Treat to Target, Treatment Duration","enrollment":52},{"nctId":"NCT02333799","phase":"PHASE3","title":"A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2015-03","conditions":"Pulmonary Tuberculosis","enrollment":109},{"nctId":"NCT06649721","phase":"PHASE3","title":"Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort","status":"ACTIVE_NOT_RECRUITING","sponsor":"Huashan Hospital","startDate":"2024-11-27","conditions":"Drug-resistant Tuberculosis, Pulmonary Tuberculosis, Rifampin-resistant Tuberculosis","enrollment":120},{"nctId":"NCT07076225","phase":"PHASE3","title":"Ultra-Short Regimen for Elderly DS-TB","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Third People's Hospital","startDate":"2025-07-25","conditions":"Pulmonary Tuberculosis","enrollment":300},{"nctId":"NCT04145258","phase":"PHASE3","title":"Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2021-02-07","conditions":"Tuberculous Meningitis","enrollment":768},{"nctId":"NCT00501150","phase":"NA","title":"Oral Antibiotic Treatment at Home Instead of Intravenous Treatment in Hospital for Resistant Gram Positive Infections","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2005-09","conditions":"Gram-positive Bacterial Infections, Staphylococcal Infections","enrollment":211},{"nctId":"NCT03086486","phase":"PHASE3","title":"Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2017-11-21","conditions":"Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant, Tuberculosis, MDR","enrollment":181},{"nctId":"NCT01734694","phase":"PHASE4","title":"Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients","status":"TERMINATED","sponsor":"Henry Ford Health System","startDate":"2011-10","conditions":"Health Care Associated Pneumonia, Osteomyelitis/Septic Arthritis, Endocarditis","enrollment":100},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1016,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Linezolid (L)","genericName":"Linezolid (L)","companyName":"Shenzhen Third People's Hospital","companyId":"shenzhen-third-people-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Used for Vancomycin-resistant Enterococcus faecium (VRE) infections, Methicillin-resistant Staphylococcus aureus (MRSA) infections, Nosocomial pneumonia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}